Veracyte Inc
VCYT24.015USD
+0.375+1.59%
Market hours （ET）Quotes delayed by 15 min
1.88BMarket Cap
56.90P/E TTM
More Details of Veracyte Inc Company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Company Info
Ticker SymbolVCYT
Company nameVeracyte Inc
IPO dateOct 30, 2013
CEOMr. Marc A. Stapley
Number of employees824
Security typeOrdinary Share
Fiscal year-endOct 30
Address6000 Shoreline Court, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16502436300
Websitehttps://www.veracyte.com/
Ticker SymbolVCYT
IPO dateOct 30, 2013
CEOMr. Marc A. Stapley
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
25.73K
+56.82%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
13.09K
-18.41%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
11.76K
+67.35%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
10.19K
-25.60%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
116.51K
-7.46%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
62.45K
+17.55%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
33.34K
-13.87%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
32.19K
+40.76%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
423.54M
95.01%
International
22.23M
4.99%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.53%
BlackRock Institutional Trust Company, N.A.
7.92%
Fidelity Management & Research Company LLC
7.88%
Artisan Partners Limited Partnership
6.69%
Wellington Management Company, LLP
4.92%
Other
62.06%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.74%
Investment Advisor/Hedge Fund
38.69%
Hedge Fund
4.35%
Research Firm
1.79%
Pension Fund
1.28%
Venture Capital
0.97%
Individual Investor
0.59%
Bank and Trust
0.44%
Sovereign Wealth Fund
0.29%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
597
84.71M
108.17%
-889.52K
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
2023Q2
516
77.28M
106.70%
-4.52M
2023Q1
533
77.62M
107.25%
-6.79M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.25M
10.53%
+52.03K
+0.64%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.21M
7.92%
-41.84K
-0.67%
Mar 31, 2025
Fidelity Management & Research Company LLC
6.17M
7.88%
+4.15M
+205.06%
Mar 31, 2025
Artisan Partners Limited Partnership
5.24M
6.69%
-1.36M
-20.60%
Mar 31, 2025
Wellington Management Company, LLP
3.85M
4.92%
-231.44K
-5.67%
Mar 31, 2025
ARK Investment Management LLC
3.21M
4.09%
-286.15K
-8.20%
May 31, 2025
ArrowMark Colorado Holdings, LLC
3.23M
4.12%
+146.65K
+4.76%
Mar 31, 2025
State Street Global Advisors (US)
3.16M
4.03%
+247.55K
+8.50%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.91M
3.72%
+28.17K
+0.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.93M
2.47%
+94.91K
+5.16%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ARK Genomic Revolution ETF
3.09%
First Trust NYSE Arca Biotechnology Index Fund
2.67%
Global X Genomics & Biotechnology ETF
2.67%
Invesco Biotechnology & Genome ETF
2.57%
WisdomTree BioRevolution Fund
1.69%
ROBO Global Healthcare Technology & Innovation ETF
1.42%
ROBO Global Artificial Intelligence ETF
1.24%
ARK Innovation ETF
0.98%
Franklin Genomic Advancements ETF
0.88%
SPDR S&P Biotech ETF
0.74%
View more
ARK Genomic Revolution ETF
Proportion3.09%
First Trust NYSE Arca Biotechnology Index Fund
Proportion2.67%
Global X Genomics & Biotechnology ETF
Proportion2.67%
Invesco Biotechnology & Genome ETF
Proportion2.57%
WisdomTree BioRevolution Fund
Proportion1.69%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.42%
ROBO Global Artificial Intelligence ETF
Proportion1.24%
ARK Innovation ETF
Proportion0.98%
Franklin Genomic Advancements ETF
Proportion0.88%
SPDR S&P Biotech ETF
Proportion0.74%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
